GLUT-1 expression and response to chemoradiotherapy in rectal cancer

International Journal of Cancer

Volumn 125, Issue 12, 2009, Pages 2778-2782

  Brophy, Sarah ^a   Sheehan, Katherine M ^a   McNamara, Deborah A ^a   Deasy, Joseph ^a   Bouchier Hayes, David J ^a   Kay, Elaine W ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

Chemoradiotherapy; GLUT 1; Hypoxia; p53; Rectal cancer

Indexed keywords

FLUOROURACIL; GLUCOSE TRANSPORTER 1; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CANCER; SCORING SYSTEM; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR REGRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROGNOSIS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 72449139255     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24693     Document Type: Article

References (38)

1. Nathanson DR, Espat NJ, Nash GM, D'Alessio M, Thaler H, Minsky BD, Enker W, Wong D, Guillem J, Cohen A, Paty PB. Evaluation of preoperative and postoperative radiotherapy on long-term functional results of straight coloanal anastomosis. Dis Colon Rectum 2003;46:888-894 (Pubitemid 36875482)
2. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, et al.. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740 (Pubitemid 39383208)
3. Engstrom PF, Benson AB, III, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, et al.. Rectal cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2005;3:492-508. (Pubitemid 44265423)
4. Glimelius B, Oliviera J. Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl 2):ii31-2.
5. Tjandra JJ, Kilkenny JW, Buie WD, Hyman N, Simmang C, Anthony T, Orsay C, Church J, Otchy D, Cohen J, Place R, Denstman F, et al. Practice parameters for the management of rectal cancer (Revised). Dis Colon Rectum 2005;48:411-423 (Pubitemid 40767859)
6. Bouzourene H, Bosman FT, Seelentag W, Matter M, Coucke P. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 2002;94:1121-1130 (Pubitemid 34150868)
7. Brown CL, Ternent CA, Thorson AG, Christensen MA, Blatchford GJ, Shashidharan M, Haynatzki GR. Response to preoperative chemoradiation in Stage II and III rectal cancer. Dis Colon Rectum 2003;46:1189-1193 (Pubitemid 37129556)
8. Chan AK, Wong A, Jenken D, Heine J, Buie D, Johnson D. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2005;61:665-677 (Pubitemid 40247960)
9. Gavioli M, Luppi G, Losi L, Bertolini F, Santantonio M, Falchi AM, D'Amico R, Conte PF, Natalini G. Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer. Dis Colon Rectum 2005;48:1851-1857 (Pubitemid 41437667)
10. Guillem JG, Chessin DB, Cohen AM, Shia J, Mazumdar M, Enker W, Paty PB, Weiser MR, Klimstra D, Saltz L, Minsky BD, Wong WD. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 2005;241:829-836 (Pubitemid 40604929)
11. Mohiuddin M, Hayne M, Regine WF, Hanna N, Hagihara PF, McGrath P, Marks GM. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys 2000;48:1075-1080 (Pubitemid 30802145)
12. Pucciarelli S, Toppan P, Friso ML, Russo V, Pasetto L, Urso E, Marino F, Ambrosi A, Lise M. Complete pathologic response following preoperative middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum 2004;47:1798-1807 (Pubitemid 40064422)
13. Valentini V, Coco C, Picciocchi A, Morganti AG, Trodella L, Ciabattoni A, Cellini F, Barbaro B, Cogliandolo S, Nuzzo G, Doglietto GB, mbesi-Impiombato F, et al. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 2002;53:664-674 (Pubitemid 34626505)
14. Wheeler JM, Dodds E, Warren BF, Cunningham C, George BD, Jones AC, Mortensen NJ. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade. Dis Colon Rectum 2004;47:2025-2031 (Pubitemid 40179060)
15. Vecchio FM, Valentini V, Minsky BD, Padula GD, Venkatraman ES, Balducci M, Micciche F, Ricci R, Morganti AG, Gambacorta MA, Maurizi F, Coco C. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 2005;62:752-760 (Pubitemid 40779765)
16. Theodoropoulos G, Wise WE, Padmanabhan A, Kerner BA, Taylor CW, Aguilar PS, Khanduja KS. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 2002;45:895-903. (Pubitemid 34761469)
17. Zlobec I, Steele R, Compton CC. VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy. Cancer 2005;104:2517-2521 (Pubitemid 41691576)
18. Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Free E. Cancer medicine. Hamilton (Canada): BC Decker, 2003.
19. Behrooz A, Ismail-Beigi F. Dual control of GLUT-1 glucose transporter gene expression by hypoxia and by inhibition of oxidative phosphorylation. J Biol Chem 1997;272:5555-5562 (Pubitemid 27102379)
20. Lin Z, Weinberg JM, Malhotra R, Merritt SE, Holzman LB, Brosius FC, III. GLUT-1 reduces hypoxia-induced apoptosis and JNK pathway activation. Am J Physiol Endocrinol Metab 2000;278:E958-E66. (Pubitemid 30366415)
21. Younes M, Lechago LV, Lechago J. Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin Cancer Res 1996;2:1151-1154 (Pubitemid 26238445)
22. Holm E, Hagmuller E, Staedt U, Schlickeiser G, Gunther HJ, Leweling H, Tokus M, Kollmar HB. Substrate balances across colonic carcinomas in humans. Cancer Res 1995;55:1373-1378
23. Hoskin PJ, Sibtain A, Daley FM, Wilson GD. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 2003;89:1290-1297 (Pubitemid 37363419)
24. Airley RE, Loncaster J, Raleigh JA, Harris AL, Davidson SE, Hunter RD, West CM, Stratford IJ. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 2003;104:85-91. (Pubitemid 36184150)
25. An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998;5:1062-1075
26. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996;379:88-91. (Pubitemid 26008141)
27. Komuro Y, Watanabe T, Hosoi Y, Matsumoto Y, Nakagawa K, Saito S, Ishihara S, Kazama S, Tsuno N, Kitayama J, Suzuki N, Tsurita G, et al. Prediction of tumor radiosensitivity in rectal carcinoma based on P53 and Ku70 expression. J Exp Clin Cancer Res 2003;22:223-228 (Pubitemid 36734180)
28. Zlobec I, Vuong T, Compton CC, Lugli A, Michel RP, Hayashi S, Jass JR. Combined analysis of VEGF and EGFR predicts complete tumor response in rectal cancer treated with preoperative radiotherapy. Br J Cancer 2008;98:450-456 (Pubitemid 351161259)
29. Jakob C, Liersch T, Meyer W, Becker H, Baretton GB, Aust DE. Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. World J Gastroenterol 2008;14:1060-1066 (Pubitemid 351325006)
30. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic Correlations Cancer 1994;73:2680-2686
31. Wibe A, Moller B, Norstein J, Carlsen E, Wiig JN, Heald RJ, Langmark F, Myrvold HE, Soreide O. A national strategic change in treatment policy for rectal cancer - implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum 2002;45:857-866
32. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986;1:1479-1482 (Pubitemid 16095660)
33. Wheeler JM, Warren BF, Mortensen NJ, Ekanyaka N, Kulacoglu H, Jones AC, George BD, Kettlewell MG. Quantification of histologic regression of rectal cancer after irradiation: a proposal for a modified staging system. Dis Colon Rectum 2002;45:1051-1056 (Pubitemid 34906789)
34. Cooper R, Sarioglu S, Sokmen S, Fuzun M, Kupelioglu A, Valentine H, Gorken IB, Airley R, West C. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer 2003;89:870-876
35. Lowe SW, Ruley HE, Jacks T, Housman DE. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-967 (Pubitemid 23289454)
36. Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, Hunter R, Stratford I, West C. Glucose transporter GLUT-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 2001;7:928-934 (Pubitemid 32708731)
37. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK, Mueller-Klieser W. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical Cancers. Cancer Res 2000;60:916-921 (Pubitemid 30129526)
38. McDonnell CO, Bouchier-Hayes DJ, Toomey D, Foley D, Kay EW, Leen E, Walsh TN. Effect of neoadjuvant chemoradiotherapy on angiogenesis in oesophageal cancer. Br J Surg 2003;90:1373-1378 (Pubitemid 37421672)